On March 18, 2026, Arvinas, Inc. reported promising Phase 1 trial results for ARV-102, showing over 50% degradation of LRRK2 in Parkinson's patients after 28 days of treatment. The trial, presented at a major conference in Copenhagen, was well tolerated, confirming ARV-102's potential for neurodegenerative diseases.